Negri Donatella R M, Michelini Zuleika, Cara Andrea
Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy.
Curr HIV Res. 2010 Jun;8(4):274-81. doi: 10.2174/157016210791208622.
Genetic immunization with lentiviral vectors is under evaluation as a means for induction of sustained immune response. Lentiviral vectors showed reduced antivector immune responses and efficiently transduce post-mitotic cells in vivo, including antigen presenting cells, such as dendritic cells and macrophages, thus providing a significant benefit over other vector-based antigen delivery platforms. Several evidences indicate that a single immunization with lentiviral vectors induces strong and sustained effector and memory T-cell immune responses, as well as antibody production. New generation of lentiviral vectors with improved biosafety profile are also under development. In particular, integration defective lentiviral vectors have been generated and used as an efficient and safe delivery system for both gene therapy and immunization purposes. Taken together, these evidences support the ongoing development of lentiviral vector-based genetic immunization strategies for safe applications in the clinic.
慢病毒载体基因免疫作为诱导持续免疫反应的一种手段正在接受评估。慢病毒载体显示出较低的抗载体免疫反应，并能在体内有效转导包括抗原呈递细胞（如树突状细胞和巨噬细胞）在内的有丝分裂后细胞，因此相对于其他基于载体的抗原递送平台具有显著优势。多项证据表明，单次慢病毒载体免疫可诱导强烈且持续的效应器和记忆性T细胞免疫反应以及抗体产生。具有改进生物安全性的新一代慢病毒载体也在研发中。特别是，已构建出整合缺陷型慢病毒载体，并将其用作基因治疗和免疫目的的高效安全递送系统。综上所述，这些证据支持了基于慢病毒载体的基因免疫策略在临床上的安全应用的持续发展。
